# Contact Peptide Biologicals — Editorial Desk

> Reach the Peptide Biologicals editorial desk regarding citations, corrections, or research-related correspondence about our Research Peptide Fundamentals digest.

Correspondence on citations, corrections, and evidence-quality questions — the things a skeptical reference desk is most useful to hear about.

## Editorial correspondence

Peptide Biologicals welcomes correspondence on the research record: a citation quoted inaccurately, a clinical trial that has published new results, a regulatory update that changes an approval status, or a peer-reviewed study on ipamorelin, PT-141, semaglutide, or tirzepatide that should be added to the [references page](/references). This class of correction, one that improves the accuracy or currency of the digest, is the most useful message this desk receives, and each is read and weighed carefully against its source.

The most actionable submissions specify the page in question, the exact passage being corrected or challenged, and the supporting reference, a DOI or PubMed identifier wherever possible. That format allows a proposed change to be checked against its source before anything on the site is altered.

**Editorial mailbox:** editors@peptidebiologicals.com

## What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Peptide Biologicals is a literature digest, not a clinical service or product vendor, so it cannot:

- Advise on, recommend, or comment on human use of any peptide discussed here.
- Suggest a dose, schedule, or route of administration for any individual.
- Evaluate whether a research finding from a cited trial applies to a specific person's situation.
- Sell, source, recommend, or help locate any compound from any supplier.
- Provide information on obtaining prescription medicines outside of a licensed prescriber-patient relationship.

Semaglutide, tirzepatide, and PT-141 (for its approved indication) are prescription medicines; ipamorelin is not an approved drug. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.

---

An evidence-grade digest: what is cited stays cited, what is not established is called unestablished, and nothing here is a recommendation.